80%、50种！我国医保目录成为创新药快速落地“加速器”

Group 1 - The dynamic adjustment mechanism for the medical insurance catalog in China has been established, focusing on new drugs launched within the last five years [1] - In 2025, 114 new drugs will be included in the medical insurance catalog, with several achieving approval and inclusion in the same year [1] Group 2 - Increased R&D investment returns are expected to encourage pharmaceutical companies to enhance innovation, particularly in areas with unmet clinical needs such as cancer and rare diseases [3] - Since 2018, the number of approved Class 1 innovative drugs has significantly increased, reaching 48 in 2024, which is over five times the number in 2018 [4] - The medical insurance catalog has become an "accelerator" for the rapid market entry of innovative drugs, contributing to the continuous expansion of China's innovative drug market [4] Group 3 - The time from drug approval to inclusion in the medical insurance catalog has decreased from approximately five years to about one year, with around 80% of innovative drugs being included within two years of market launch [6] - Medical insurance access has become crucial for pharmaceutical companies' market expansion, allowing innovative drugs to quickly gain market share while less valuable drugs are removed from the catalog [6] - As of 2025, the total number of drugs in the national medical insurance catalog has reached 3,253, with Class 1 innovative drugs increasing to 50 [6]